Foundation Medicine and European Organisation for Research and Treatment of Cancer (EORTC) Announce Collaboration to Advance Precision Medicine Using Comprehensive Genomic Profiling to Facilitate Clinical Trial Enrollment
"Oncology clinical trials are essential to advancing research and drug development while enabling patient access to potential clinical treatment options. Yet, currently only a small fraction of cancer patients enroll in clinical trials," said
The collaboration brings together the EORTC, an independent, non-profit clinical research organization in cancer, and
"SPECTA serves as a shared and integrated translational and clinical research infrastructure for knowledge development and ultimately allows matching patients to clinical trials based on both their clinical characteristics and the molecular profiles of their tumors," said
Under the agreement,
About EORTC
Through translational and clinical research, the EORTC offers an integrated approach to drug development, drug evaluation programmes and medical practices. EORTC Headquarters, a unique pan-European clinical research infrastructure, is based in
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the value and performance capabilities of Foundation Medicine's comprehensive genomic profiling (CGP) assays; the ability of Foundation Medicine's CGP assays to identify patients eligible to participate in specific clinical trials, help improve efficiencies, and streamline clinical trial enrollment; and the ability of a clinical trial to accelerate precision oncology, expand access to therapies, or improve cancer care. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risk that Foundation Medicine's CGP assays and services will not be able to identify genomic alterations in the same manner as prior clinical data or prior experience; clinical trial enrollment does not become more efficient or increase in the expected manner; and the risks described under the caption "Risk Factors" in Foundation Medicine's Annual Report on Form 10-K for the year ended
View source version on businesswire.com: http://www.businesswire.com/news/home/20180130005042/en/
Media Contact:
pr@foundationmedicine.com
or
Investor Contact:
ir@foundationmedicine.com
or
communication@eortc.be
Source:
News Provided by Acquire Media